Learn about the global pegfilgrastim biosimilars market through The Business Research Company, which provides information on pegfilgrastim biosimilars market size, pegfilgrastim biosimilars market drivers and restraints, pegfilgrastim biosimilars market players, the COVID-19 impact on the pegfilgrastim biosimilars market, and more.

The pegfilgrastim biosimilars market is expected to grow from $0.90 billion in 2020 to $1.80 billion in 2025 at a rate of 14.8%. The growth in the pegfilgrastim biosimilars market is mainly due to an increased prevalence of cancer and increasing adoption of the biosimilars. The pegfilgrastim biosimilars market is then expected to grow at a CAGR of 17.5% from 2025 and reach $4.04 billion in 2030.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the pegfilgrastim biosimilars market during the forecast period.

Request A Sample For The Global Pegfilgrastim Biosimilars Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3428&type=smp

The pegfilgrastim biosimilars market consists of the sales of pegfilgrastim biosimilars and related services by entities (organizations, sole traders and partnerships) that use them for the treatment of febrile neutropenia – a life-threatening complication of cancer chemotherapy and to increase the production of infection-fighting white blood cells following transplantation. It is a recombinant human granulocyte colony stimulating factor (G-CSF) and helps to stimulate the production of infection-fighting white blood cells (neutrophils) for the treatment of cancer patients undergoing chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants

Global pegfilgrastim biosimilars market segments include:

By Application: Chemotherapy Treatment, Transplantation, Others

By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the pegfilgrastim biosimilars market, accounting for 51.2% of the total in 2021

The pegfilgrastim biosimilar market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials for biosimilars. Research and development is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the market in the form of new and effective biosimilars.

TBRC’s pegfilgrastim biosimilars market report covers:

Major Market Players: Coherus BioSciences, Sandoz (Novartis), Biocon/Mylan, Intas Biopharmaceuticals Ltd, Mundipharma GmbH

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Pegfilgrastim Biosimilars Market Report 2022  is one of a series of new reports from The Business Research Company that provides pegfilgrastim biosimilars market overviews, analyzes and forecasts market size, share, pegfilgrastim biosimilars market players, pegfilgrastim biosimilars market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s pegfilgrastim biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Biosimilar Monoclonal Antibodies Global Market Report 2022

Rituximab Biosimilars Global Market Report 2022

Biosimilar Lymphocyte Modulator Global Market Report 2022

Interested To Know More About The Business Research Company?

The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: